Form 4: Armata Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Robin Kramer, a director of Armata Pharmaceuticals, Inc., reported the acquisition of stock options.
Summary
- On February 5, 2025, Robin Kramer, a director of Armata Pharmaceuticals, Inc., acquired 54,343 stock options with an exercise price of $2.04.
- These options vest in two tranches: 50% on February 5, 2026, and the remaining 50% on February 5, 2027, contingent upon continuous service.
- The options expire on February 5, 2035.
- Following the transaction, Kramer directly owns 54,343 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. The vesting schedule suggests a long-term commitment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of transaction: Robin Kramer acquired stock options. |
| 02/05/2026 | 50% of the acquired stock options vest. |
| 02/05/2027 | Remaining 50% of the acquired stock options vest. |
| 02/05/2035 | Expiration date of the acquired stock options. |
| 02/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.